What does Myriad Genetics do and what are its main business segments?

Did Myriad Genetics beat or miss consensus estimates last quarter?

What is Myriad Genetics's latest dividend and current dividend yield?

What were the key takeaways from Myriad Genetics’s earnings call?

What were the key takeaways from Myriad Genetics's earnings call?

What is Myriad Genetics's gross profit margin?

What is the market's earnings forecast for Myriad Genetics next quarter?

What guidance did Myriad Genetics's management provide for the next earnings period?

- **Q4 2025 Strong Execution**: Revenue $209.8M, 9% test volume growth in hereditary cancer, and 9% GeneSight volume growth despite UHC headwinds.
- **2026 Growth Catalysts**: $35M+ investment in commercial teams, 3 major product launches (MRD, AI-Prolaris, FirstGene), and prenatal recovery.
- **MRD Alpha Launch**: Q1 2026 with select centers; tracking repeat orders, operational efficiency, and user experience.
- **Financial Discipline**: 2026 EBITDA guidance $37-49M, balanced growth investment with profitability focus.
- **Long-Term Vision**: High single-digit to low double-digit growth in 2027+ via MRD, AI, and expanded prenatal portfolio.

**【CEO Summary Section】**
- Q4 2025 revenue: $209.8 million, above high end of preannounced range, with 4% underlying growth excluding GeneSight headwinds.
- Test volume growth: 9% year-over-year in hereditary cancer, 9% in GeneSight, driven by unaffected market expansion and commercial execution.
- Key launches: Expanded MyRisk panel (Q4 2025), AI-enhanced Prolaris (Q2 2026), Precise MRD Alpha launch (Q1 2026), and FirstGene (H2 2026).
- 2026 strategy: $35M+ investment in commercial capabilities, focusing on cancer care continuum, prenatal recovery, and AI/MRD innovation.

**【CFO Financial Commentary】**
- Q4 2025: Adjusted EBITDA $14.3M, adjusted EPS $0.04, gross margin 70%, OpEx down $7M YoY.
- 2026 guidance: Revenue $860-880M, gross margin 68-69%, EBITDA $37-49M.
- Q1 2026: Revenue $200-203M, prenatal volume decline expected, sequential growth from Q2+.
- Financial priorities: Balancing growth investment with profitability, maintaining $225M liquidity.

**【Q&A Key Highlights】**
- **MRD Launch**: Alpha phase starting Q1 2026 with select community oncology centers; metrics tracked include repeat orders, operational efficiency, and user experience. MolDX submissions planned for H2 2026.
- **Prenatal Recovery**: Q1 2026 volume decline due to Q2 2025 system disruption; reactivation efforts underway, with full commercial launch of FirstGene in H2 2026.
- **ASP Dynamics**: 1-2% YoY decline expected in 2026 due to payer mix (unaffected market ASP 10% lower than affected), offset by volume growth in hereditary cancer and GeneSight.
- **Sales Expansion**: Over $35M investment in oncology salesforce to support MRD, Prolaris, and MyRisk launches; prenatal team expansion in Q2 2026.
- **Long-Term Growth**: High single-digit to low double-digit growth potential in 2027+ driven by MRD, AI-enabled Prolaris, and FirstGene launches.

Myriad Genetics, Inc.(MYGN)-20260224-2025 Q4 Earnings call transcript

- **Cancer Testing Growth**: MyRisk volumes up 16% (affected) / 11% (unaffected) YoY, with expanded panel launch in November driving 2026 growth.
- **Strategic Investments**: $35M+ allocated to commercial expansion, MRD R&D, and AI-driven Prolaris launch in H1 2026.
- **Financial Resilience**: 70.1% gross margin, $10.3M EBITDA, and reaffirmed 2025 guidance despite 4% top-line decline.
- **2026 Outlook**: Target 5%+ revenue growth above OpEx expansion, with key launches in MRD, prenatal, and mental health.

**【CEO Summary Section】**
- Q3 2025 revenue of $206 million (-4% YoY), stable when excluding headwinds from UnitedHealthcare's GeneSight policy and European EndoPredict divestiture. Adjusted for these factors, underlying growth was 5% YoY.
- MyRisk hereditary cancer testing volumes grew 16% (affected market) and 11% (unaffected market) YoY, driven by EMR workflow improvements and expanded panel launch in November.
- GeneSight mental health testing volumes grew 8% YoY, with 37,000+ ordering clinicians, despite ongoing UnitedHealthcare coverage challenges.
- Strategic focus on cancer care continuum: $35M+ investment in commercial expansion, MRD R&D, and partnerships (e.g., SOPHiA GENETICS for liquid biopsy CDx).
- 2026 launches planned for ultrasensitive MRD test (breast cancer), AI-enabled Prolaris, and expanded MyRisk panel with 15 new actionable genes.

**【CFO Financial Commentary】**
- Q3 2025 GAAP net income: $420 million; Non-GAAP EPS: $1.08 (vs. $0.95 consensus).
- Adjusted EBITDA: $10.3 million; Free cash flow: $18.6 million (timing-driven collections).
- Gross margin: 70.1% (stable vs. prior quarters); OpEx: $139.7 million (-$1M YoY due to cost discipline).
- Full-year 2025 guidance reaffirmed: Revenue $818-828M, Gross margin 69.5-70%, OpEx $562-568M, EBITDA $27-33M.
- 2026 investment plan: Expand commercial team, enhance launch capabilities, and fund MRD clinical trials.

**【Q&A Highlights】**
- **Cancer Care Growth**: CEO emphasized 5%+ revenue growth target above OpEx expansion, with focus on MyRisk, MRD, and AI-driven Prolaris.
- **NIPT Market Dynamics**: FirstGene 2-in-1 prenatal screen (NIPT + carrier) to launch in 2026, targeting 8-week gestation with 1-week turnaround. Company expects to regain market share through workflow improvements and new product innovation.
- **GeneSight Reimbursement**: 9 states now cover GeneSight under biomarker laws (e.g., California Medicaid), but UnitedHealthcare policy remains unchanged. Team maintains disciplined investment while awaiting potential policy reversal.
- **MRD Pipeline**: Ultrasensitive Precise MRD test for breast cancer expected in H1 2026, with data showing 87% 3-year survival in oligometastatic RCC patients.
- **Operational Efficiency**: Organizational redesign reduces management layers, reallocating $35M+ to growth initiatives while maintaining 70%+ gross margin.

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 5% YoY (excluding UHC impact), driven by oncology (+14% MyRisk HCT) and recovering GeneSight (+5% YoY).
- **Strategic Shift**: Cancer Care Continuum focus with 3 pillars: oncology expansion, above-market prenatal/mental health growth, and disciplined profitability.
- **Financial Strength**: Gross margin 71.5% (up 140bps YoY), $14.5 million adjusted EBITDA, and $200 million credit facility for growth funding.
- **Upcoming Launches**: MRD early access Q1 2026, PATHOMIQ prostate cancer AI partnership, and full commercial launch of FirstGene prenatal screen 2026.
- **Risk Management**: Non-cash $317 million goodwill impairment due to market cap decline, no impact on business outlook.

**【CEO Summary Section】**
- **Q2 2025 Financial Highlights**: Revenue of $213 million (+5% YoY, excluding UHC GeneSight impact), adjusted EBITDA of $14.5 million (+24% YoY), and adjusted EPS of $0.05.
- **Strategic Focus**: Shift to Cancer Care Continuum (CCC) with 3 pillars: oncology growth, prenatal/mental health above-market growth, and disciplined profitability. 
- **Key Growth Drivers**: MyRisk HCT volume up 14% YoY, GeneSight rebounding to 5% YoY growth, and prenatal system issues resolved.
- **New Strategy Details**: Expansion into therapy selection (CGP, HRD), IO monitoring, and MRD; partnership with PATHOMIQ for prostate cancer AI integration.
- **Guidance Update**: Full-year 2025 revenue raised to $818-828 million, gross margin 69.5-70%, and EBITDA $27-33 million.

**【COO Operational Update】**
- **Oncology Performance**: MyRisk HCT unaffected volumes +3% YoY (EMR workflow improvements), Prolaris +4% YoY, and MRD early access launch Q1 2026.
- **Prenatal Recovery**: Fixed order management system issue; Prequel NIPS at 8 weeks and Foresight expanded carrier screening driving 7% YoY revenue growth.
- **GeneSight Momentum**: 5% YoY volume growth post Q1 realignment, 36,000+ ordering clinicians, and Medi-Cal coverage expansion.

**【CFO Financial Commentary】**
- **Gross Margin Expansion**: 71.5% (up 140bps YoY) driven by pricing improvements and lab efficiencies.
- **Cost Control**: Adjusted OpEx flat YoY, with focus on strategic investments.
- **Capital Structure**: $200 million term loan with OrbiMed (11% interest rate), replacing ABL facility.
- **Impairment Charge**: $317 million non-cash goodwill write-down due to market cap decline,不影响业务前景.

**【Q&A Key Highlights】**
- **Strategic KPIs**: Long-term 5-year goal of high single-digit to low double-digit revenue growth; oncology pipeline expansion via partnerships (e.g., PATHOMIQ).
- **GeneSight Outlook**: UnitedHealthcare policy review expected Q4 2025; 49 new payer coverage wins YTD.
- **MRD Launch**: Ultrasensitive Precise MRD early access Q1 2026, targeting breast cancer patients.
- **Portfolio Strategy**: No immediate divestitures; focus on oncology growth while maintaining prenatal/mental health market share.


Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript

- **Revenue adjustment reveals underlying strength**: Q1 2025 adjusted growth of 5% (excluding UHC impact), driven by 10% YoY growth in ForeSight/Prequel and 11% in myRisk oncology.
- **GeneSight headwinds materialize**: UHC policy change caused $10M Q1 revenue decline; 2025 guidance reduced by $35M due to GeneSight and unaffected hereditary cancer underperformance.
- **New product pipeline acceleration**: First gene (carrier screening/NIPS) launch in Q2 2025; AI-enabled Prolaris for prostate biopsy by end-2025.
- **Cost control and liquidity**: OpEx reduced by $25M midpoint; $92M cash on hand with sufficient liquidity for 2025.

**【CEO Summary Section】**
- Q1 2025 revenue: $196 million (-3% YoY), with adjusted growth of 5% excluding UHC impact and other one-time factors.
- Key highlights: 10% YoY growth in ForeSight and Prequel volumes; 11% YoY growth in myRisk oncology test volumes.
- Challenges: GeneSight test volume down 20% YoY due to UHC policy change; myRisk for unaffected individuals flat YoY due to slower-than-expected EMR integration ramp.
- New product pipeline: Launching first gene (combined carrier screening/NIPS) in Q2 2025; PRECISE MRD clinical data presented at AACR, targeting H1 2026 launch; AI-enabled Prolaris test for prostate cancer biopsy expected by end-2025.

**【COO Business Review】**
- **Prenatal Testing**: 11% YoY revenue growth, driven by PreQoW8 launch and carrier screening expansion.
- **Oncology**: 2% YoY decline in hereditary cancer testing, offset by 11% growth in myRisk for cancer patients.
- **Women's Health**: $87 million revenue (+4% YoY), with strength in prenatal but weakness in unaffected hereditary cancer due to EMR integration delays.
- **Pharmacogenomics**: GeneSight revenue down 20% YoY, impacted by UHC policy change and reduced commercial spend.

**【CFO Financial Commentary】**
- Q1 2025: Adjusted EBITDA near breakeven; cash burn of $10 million, ending with $92 million in cash.
- Updated 2025 guidance: Revenue $807-823 million (-$35M midpoint from prior guidance); adjusted OpEx $555-565 million (-$25M midpoint).
- Key financial metrics: 69% gross margin (up 50bps YoY); $29.3 million tax benefit from IRS audit resolution.
- Cash outlook: Sufficient liquidity for 2025, exploring balance sheet strengthening opportunities.

**【Q&A Highlights】**
- **GeneSight Impact**: UHC policy change caused $10M Q1 revenue headwind; 2025 guidance reflects $35M reduction in GeneSight and unaffected hereditary cancer volumes.
- **Strategic Adjustments**: Reducing commercial spend in GeneSight; reallocating resources to high-growth products like first gene and MRD.
- **EMR Integration Challenges**: 15+ EMR vendors require account-by-account workflow solutions; expects gradual improvement in 2025.
- **MRD Progress**: PRECISE MRD clinical data presented at AACR; targeting H1 2026 launch of first MRD test.
- **Liquidity**: No near-term ABL covenant concerns; streamlined working capital reduces cash needs.

Myriad Genetics (MYGN)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 11% FY24, 7% Q4, driven by hereditary cancer, prenatal, and GeneSight testing.
- **Strategic AI Partnership**: PATHOMIQ collaboration to enhance prostate cancer diagnostics with AI-powered post-treatment testing.
- **Product Pipeline**: 2025 launches of FirstGene and Precise MRD, with Prequel showing early adoption.
- **Financial Health**: 72% Q4 gross margin, $40M full-year EBITDA, and $158M liquidity.
- **Challenges**: UnitedHealthcare policy headwind in Q1 2025, offset by long-term growth initiatives.

**【CEO Summary Section】**
- **Revenue Growth**: 11% year-over-year in 2024, driven by hereditary cancer (6%), prenatal (12%), and GeneSight (14%) testing. Q4 revenue grew 7% YoY to $200M+.
- **Strategic Partnerships**: Exclusive AI partnership with PATHOMIQ for prostate cancer diagnostics, enhancing post-treatment testing capabilities.
- **Product Launches**: Prequel (8-week prenatal test) and expanded carrier screening (Foresight Universal Plus) launched in 2024. Upcoming 2025 launches include FirstGene and Precise MRD.
- **Market Position**: Leading in oncology with MyRisk, MyChoice, and Prolaris; 72 Net Promoter Score across providers.

**【CFO Financial Commentary】**
- **Q4 Financials**: $200M+ revenue, 7% YoY growth; $0.03 adjusted EPS (positive for 3rd consecutive quarter). Full-year 2024: $760M revenue, $0.14 EPS, $40M EBITDA.
- **Gross Margin**: 72% in Q4 (up 300bps YoY), driven by stable ASPs and lab efficiency.
- **2025 Guidance**: $840-860M revenue, 69.5-70.5% gross margin, $0.07-0.11 EPS. Q1 2025: $196-204M revenue, $0.04-0.08 loss.
- **Liquidity**: $158M cash, reversing $21M contingent liability with Ravgen.

**【Q&A Highlights】**
- **R&D Investment**: 25% YoY increase for clinical trials (e.g., Precise MRD), offset by SG&A belt-tightening.
- **GeneSight Resilience**: 23% YoY growth despite UnitedHealthcare policy change; 30,000+ clinicians using test.
- **Prolaris Momentum**: 24% MyRisk effective growth YoY; PATHOMIQ AI partnership to accelerate Level 1 evidence for Prolaris.
- **UnitedHealthcare Impact**: Q1 2025 faces $7M headwind from 2024 payer wins; expect 2026 return to 12%+ revenue growth.
- **AI Expansion**: PATHOMIQ's image-based AI platform applicable to all solid tumors, complementing molecular diagnostics.

Actual												-0.08	-0.06	0.12	-0.02	-0.02	-0.03	0.04	-0.19	-0.12	-0.21	-0.08	-0.03	0.04	-0.01	0.05	0.06	0.03	-0.03	0.05	0	0.04
Forecast												0.0075	-0.1513	-0.1011	-0.0178	-0.0237	-0.083	0.025	-0.04	-0.1633	-0.1933	-0.0811	-0.0756	0.0142	-0.1042	-0.0117	0.0187	0.0304	-0.0545	-0.0078	-0.0122	-0.0149
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1166.67%	+60.34%	+218.69%	-12.36%	+15.61%	+63.86%	+60.00%	-375.00%	+26.52%	-8.64%	+1.36%	+60.32%	+181.69%	+90.40%	+527.35%	+220.86%	-1.32%	+44.95%	+741.03%	+100.00%	+368.46%

MYGN

MYGN fundamentals

MYGN Q4 2025 Earnings

Earnings Call

You can ask Aime

MYGN

MYGN fundamentals

MYGN Q4 2025 Earnings

Earnings Call

MYGN Earnings Call Summary for Q4/20254:30 PM on Feb 23, 2026

MYGN Earnings Call Summary for Q3/20254:30 PM on Nov 3, 2025

MYGN Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

MYGN Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

MYGN Earnings Call Summary for Q4/20244:30 PM on Feb 24, 2025

You can ask Aime